Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ayala Pharmaceuticals Inc (OP: ADXS ) 0.0895 UNCHANGED Streaming Delayed Price Updated: 12:37 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ayala Pharmaceuticals Inc Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations May 09, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome March 26, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 From Immunome, Inc. Via Business Wire Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors November 06, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 October 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Closing of Merger with Biosight October 19, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 August 01, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement July 27, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors July 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting June 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 25, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update May 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 27, 2023 Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee March 03, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022 February 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement October 19, 2022 From Ayala Pharmaceuticals Via GlobeNewswire ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS March 28, 2022 From Kahn Swick & Foti, LLC Via Business Wire INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS; Shareholders are Encouraged to Contact the Firm July 22, 2021 NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Lonestar Resources US Inc. (OTCQX:LONE)... From Halper Sadeh LLP Via AccessWire Topics Fraud Exposures Legal INVESTIGATION ALERT: Halper Sadeh LLP Investigates JAX, STMP, IKNX, ADXS; Shareholders are Encouraged to Contact the Firm July 11, 2021 NEW YORK, NY / ACCESSWIRE / July 11, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: J. Alexander's Holdings, Inc. (NYSE:JAX)... From Halper Sadeh LLP Via AccessWire Topics Fraud Exposures Legal INVESTIGATION ALERT: Halper Sadeh LLP Investigates CORE, CAI, BOCH, ADXS; Shareholders are Encouraged to Contact the Firm July 10, 2021 NEW YORK, NY / ACCESSWIRE / July 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc.... From Halper Sadeh LLP Via AccessWire Topics Fraud Exposures Legal ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS July 07, 2021 From Kahn Swick & Foti, LLC Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.